Payment overview · 2025
General Payments
$6,397.44
246 reported records · 39 companies
Healthcare provider profile · identity verified
Warren Banta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · LOS ANGELES, CA · NPI 1861695678
Verified facts
What the public records show
CMS Open Payments records show Warren Banta, MD received $6,397.44 in general payments during 2025 across 246 reported records.
Novartis Pharmaceuticals Corporation accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 75 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Calquence, Imbruvica, Inlyta, Jakafi, Kisqali, Lenvima, Ninlaro, Orgovyx, Reblozyl, Sarclisa, Venclexta, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Orgovyx by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Calquence by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Pomalyst by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 17361 records involving 5696 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Reblozyl by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1732 records involving 943 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Reblozyl by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lenvima by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SARCLISA as an associated drug or biological on 7155 records involving 4028 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Sarclisa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Venclexta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Verzenio by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lenvima by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1175 records involving 979 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Reblozyl by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kisqali by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INLYTA as an associated drug or biological on 2646 records involving 1964 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Inlyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xtandi by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 17129 records involving 6223 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Orgovyx by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NINLARO as an associated drug or biological on 3835 records involving 2551 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ninlaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,370.99 | 21.4% | 35 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $655.77 | 10.2% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $618.83 | 9.7% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $414.15 | 6.5% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $336.54 | 5.3% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $288.79 | 4.5% | 15 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $269.46 | 4.2% | 12 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $228.17 | 3.6% | 7 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $201.48 | 3.1% | 9 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $161.30 | 2.5% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $146.20 | 2.3% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $139.05 | 2.2% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $137.92 | 2.2% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $114.34 | 1.8% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $110.94 | 1.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.51 | 1.7% | 5 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $99.73 | 1.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $98.28 | 1.5% | 5 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $97.67 | 1.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $84.85 | 1.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $67.83 | 1.1% | 3 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $60.20 | 0.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.31 | 0.9% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $50.97 | 0.8% | 2 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $50.65 | 0.8% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $50.52 | 0.8% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $49.57 | 0.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.51 | 0.7% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $43.99 | 0.7% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $32.12 | 0.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $31.41 | 0.5% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $31.31 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.73 | 0.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.23 | 0.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $21.83 | 0.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.29 | 0.3% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.53 | 0.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.20 | 0.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.27 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,297.49 | 233 |
| Long term medical supply or device loan | $999.96 | 12 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $1,156.42 | 23 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $493.08 | 14 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $381.64 | 20 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $367.13 | 15 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $337.95 | 13 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $288.79 | 15 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $278.90 | 14 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $257.59 | 10 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $251.80 | 10 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $210.88 | 9 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $205.03 | 8 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $189.76 | 7 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $182.70 | 8 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $161.30 | 7 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $153.63 | 8 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $150.55 | 5 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $150.55 | 5 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $146.20 | 7 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $137.92 | 5 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $133.16 | 5 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $118.49 | 5 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $113.46 | 4 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $104.07 | 6 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $99.73 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $98.28 | 5 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological, Drug | Janssen Biotech, Inc. | $97.54 | 6 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.22 | 4 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.22 | 4 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $90.78 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $89.32 | 5 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $86.02 | 4 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $73.80 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $73.80 | 3 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $69.40 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $68.07 | 4 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $61.57 | 3 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $60.20 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $52.27 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $50.97 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $50.94 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $49.57 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $45.76 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $43.83 | 3 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.67 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $32.42 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $31.31 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $31.31 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $10.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CALQUENCE calquence |
2025 | Calquence | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 78 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INLYTA inlyta |
2025 | Inlyta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NINLARO ninlaro |
2025 | Ninlaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REBLOZYL reblozyl |
2025 | Reblozyl | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SARCLISA sarclisa |
2025 | Sarclisa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 17361 supporting records · 5696 recipient NPIs · example record 1184377709 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1732 supporting records · 943 recipient NPIs · example record 1184377805 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | SARCLISA open payments reported associated product |
CMS Open Payments — General Payments 7155 supporting records · 4028 recipient NPIs · example record 1233194888 |
Sarclisa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1175 supporting records · 979 recipient NPIs · example record 1237992280 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | INLYTA open payments reported associated product |
CMS Open Payments — General Payments 2646 supporting records · 1964 recipient NPIs · example record 1228795917 |
Inlyta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 17129 supporting records · 6223 recipient NPIs · example record 1176593507 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | NINLARO open payments reported associated product |
CMS Open Payments — General Payments 3835 supporting records · 2551 recipient NPIs · example record 1223616278 |
Ninlaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 451 | 126 |
| Ondansetron Hcl | Ondansetron Hcl | 186 | 108 |
| Procrit | Epoetin Alfa | 158 | 39 |
| Hydroxyurea | Hydroxyurea | 128 | 31 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 110 | 70 |
| Prednisone | Prednisone | 99 | 26 |
| Zarxio | Filgrastim-Sndz | 86 | 29 |
| Tamoxifen Citrate | Tamoxifen Citrate | 84 | 23 |
| Dexamethasone | Dexamethasone | 78 | 35 |
| Imbruvica | Ibrutinib | 78 | suppressed |
| Eliquis | Apixaban | 76 | 16 |
| Letrozole | Letrozole | 76 | 24 |
| Jakafi | Ruxolitinib Phosphate | 62 | suppressed |
| Orgovyx | Relugolix | 62 | suppressed |
| Lenalidomide | Lenalidomide | 50 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 48 | suppressed |
| Gabapentin | Gabapentin | 45 | suppressed |
| Promacta | Eltrombopag Olamine | 40 | suppressed |
| Zoledronic Acid | Zoledronic Acid | 40 | 21 |
| Acyclovir | Acyclovir | 38 | suppressed |
| Brukinsa | Zanubrutinib | 34 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 33 | suppressed |
| Calquence | Acalabrutinib Maleate | 32 | suppressed |
| Tasigna | Nilotinib Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Xtandi | Enzalutamide | 30 | suppressed |
| Pomalyst | Pomalidomide | 29 | suppressed |
| Sarclisa | Isatuximab-Irfc | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Akynzeo | Netupitant/Palonosetron Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | 11 |
| Ninlaro | Ixazomib Citrate | 23 | suppressed |
| Inlyta | Axitinib | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Lupron Depot | Leuprolide Acetate | 18 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 17 | suppressed |
| Lenvima | Lenvatinib Mesylate | 17 | suppressed |
| Exemestane | Exemestane | 16 | suppressed |
| Eligard | Leuprolide Acetate | 15 | suppressed |
| Famotidine | Famotidine/Pf | 15 | suppressed |
| Kisqali | Ribociclib Succinate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 12 |
| Lumakras | Sotorasib | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Verzenio | Abemaciclib | 15 | suppressed |
| Granisetron Hcl | Granisetron Hcl/Pf | 14 | suppressed |
| Reblozyl | Luspatercept-Aamt | 14 | suppressed |
| Xgeva | Denosumab | 13 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Revlimid | Lenalidomide | 12 | suppressed |
| Sancuso | Granisetron | 11 | suppressed |
| Venclexta | Venetoclax | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,397.44 · 246 records | Novartis Pharmaceuticals Corporation | ACCRUFER, ADCETRIS, AKEEGA, BALVERSA, BESREMI, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, CALQUENCE, CARVYKTI, DARZALEX, Doptelet, ELREXFIO, ENHERTU, EPKINLY, ERLEADA, FOTIVDA, FRUZAQLA, Fabhalta, IBRANCE, ICLUSIG, IMBRUVICA, INLYTA, INQOVI, Itovebi, JAKAFI, JAYPIRCA, KEYTRUDA, KISQALI, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LYNPARZA, Lenvima, MEKTOVI, NERLYNX, NINLARO, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Onivyde, PADCEV, PLUVICTO, PYRUKYND, Polivy, QINLOCK, REBLOZYL, ROMVIMZA, RYBREVANT, SARCLISA, SCEMBLIX, Stivarga, TALVEY, TALZENNA, TECVAYLI, TUKYSA, Tecentriq Hybreza, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vitrakvi, Vonjo, WAYRILZ, WELIREG, XALKORI, XPOVIO, XTANDI, Xofigo, Yescarta, clonoSEQ | 32 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error